Sugi Predict

Sugi Predict / Compounds / SCHEMBL57245

SCHEMBL57245

SCHEMBL57245

O=C(Oc1ccc(F)cc1)Oc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ ATM Q13315 1/20 0.47
▸ CES2 O00748 1/20 0.46
▸ CES1 P23141 1/20 0.46
▸ CA1 P00915 2/20 0.42
▸ CA2 P00918 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ FAAH O00519 1/20 0.42
▸ NR4A2 P43354 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ ELANE P08246 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14424402 0.91 ALOX15 (0.50) KMT2AMEN1ATMALDH1A1SMN1; SMN2
SCHEMBL5865254 0.90 KMT2A (0.44) KMT2AMEN1ATMCES2CES1
Guanidine SCHEMBL27421363 0.89 KMT2A (0.45) KMT2AMEN1ATMCES2CES1
SCHEMBL10709297 0.89 NFE2L2 (0.53) KMT2AMEN1CES2CES1CA1
SCHEMBL13246362 0.89 LMNA (0.57) KMT2AMEN1ALDH1A1SMN1; SMN2CYP1A2
SCHEMBL10710114 0.87 KMT2A (0.46) KMT2AMEN1ATMCES2CES1
SCHEMBL3946410 0.86 ALDH1A1 (0.49) KMT2AMEN1ATMALDH1A1KDM4E
SCHEMBL10708455 0.85 KIF11 (0.56) CES2CES1CA1CA2ALDH1A1
SCHEMBL18671115 0.84 KMT2A (0.44) KMT2AMEN1ATMCES2CES1
SCHEMBL10715147 0.84 F2 (0.46) KMT2AMEN1CA1CA2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023179324-A1 ELECTROLYTIC SOLUTION CONTAINING FLUOROBENZENE CARBONATE, AND BATTERY COMPOSED OF ELECTROLYTIC SOLUTION 香河昆仑新能源材料股份有限公司 2023-09-28 — — WO claimed
EP-2730618-B1 Process for producing polycarbonate compositions SABIC GLOBAL TECHNOLOGIES BV (NL) 2016-10-12 — — EP claimed
EP-2951299-A1 CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA The Regents of The University of Colorado, A Body Corporate (US) 2015-12-09 — — EP claimed
US-9051463-B2 Process for producing polycarbonate compositions SABIC GLOBAL TECHNOLOGIES B.V. (NL) 2015-06-09 — — US claimed
WO-2014120770-A1 CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA THE REGENTS OF UNIVERSITY OF COLORADO (US) 2014-08-07 — — WO claimed
EP-1572728-B1 POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF MOUNTAIN VIEW PHARMACEUTICALS (US) 2014-06-25 — — EP claimed
WO-2014072923-A1 PROCESS FOR PRODUCING POLYCARBONATE COMPOSITIONS SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2014-05-15 — — WO claimed
EP-2730618-A1 Process for producing polycarbonate compositions SABIC Innovative Plastics IP B.V. (NL) 2014-05-14 — — EP claimed
US-20140128526-A1 PROCESS FOR PRODUCING POLYCARBONATE COMPOSITIONS SABIC INNOVATIVE PLASTICS IP B.V. (NL) 2014-05-08 — — US claimed
US-20120114742-A1 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2012-05-10 — — US claimed
US-6569985-B2 Multistage; oligomerization using tetraalykyphosphorium catalyst and Group 1a hydroxide catalyst GENERAL ELECTRIC COMPANY 2003-05-27 — — US claimed
US-20030092755-A1 Novel prodrugs for antimicrobial amidines NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-05-15 — — US claimed
US-20030065129-A1 Method for making polycarbonate GENERAL ELECTRIC COMPANY 2003-04-03 — — US claimed
WO-2003014188-A1 METHOD FOR MAKING POLYCARBONATE GENERAL ELECTRIC COMPANY (US) 2003-02-20 — — WO claimed
US-20030012777-A1 Polymer conjugates of proteinases MOUNTAIN VIEW PHARMACEUTICALS, INC. 2003-01-16 — — US claimed
WO-2003002716-A2 POLYMER STABILIZED PROTEINASES MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) 2003-01-09 — — WO claimed
EP-1242059-A2 NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2002-09-25 — — EP claimed
US-6399739-B1 PROCESS CONTROL USING COMPUTERS GENERAL ELECTRIC COMPANY 2002-06-04 — — US claimed
US-20020019437-A1 Novel prodrugs for antimicrobial amidines NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2002-02-14 — — US claimed
WO-2001003685-A2 NOVEL PRODRUGS FOR ANTIMICROBIAL AMIDINES THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2001-01-18 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120114742-A1 Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof CD14, HLA-C, HLA-A KMT2A 2567/4885MEN1 1245/4885ATM 4060/4885
US-20030012777-A1 Polymer conjugates of proteinases PRNP, PRSS3, PRSS1 KMT2A 2115/4885MEN1 4007/4885ATM 3317/4885
US-20030092755-A1 Novel prodrugs for antimicrobial amidines NR1H3, APEH, NR1H2 KMT2A 3680/4885MEN1 4773/4885ATM 4230/4885
US-20020019437-A1 Novel prodrugs for antimicrobial amidines NR1H3, APEH, NR1H2 KMT2A 3680/4885MEN1 4773/4885ATM 4230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.